- Location
abiraterone acetate
"-
Johnson & Johnson Has Completed The Acquisition of Aragon Pharmaceuticals
Aug 22, 2013Johnson & Johnson has completed the acquisition of Aragon Pharmaceuticals, a pharmaceutical discovery and development company focused on drugs to hormonally-driven cancers. The Janssen Research & Development will manage compound ...
-
EC Has Approved Broader Indication of Janssen-Cilag International's Oral
Jan 15, 2013The European Commission (EC) has approved broader indication of Janssen-Cilag International's oral, once-daily medication Zytiga (abiraterone acetate). Licence extension includes the use of Zytiga as a combination therapy along with ...
Tags: Zytiga, Janssen Europe, medical
-
Janssen Research and Development Has Received The Priority Review
Aug 30, 2012Janssen Research and Development has received the Priority Review for the supplemental New Drug Application (sNDA) for ZYTIGA from US Food and Drug Administration (FDA). Zytiga (abiraterone acetate) is administered in combination with ...
Tags: sNDA, priority review, FDA
-
Janssen Research Submitted a Supplemental New Drug Application to FDA for Zytiga
Jun 18, 2012Janssen Research & Development has announced that it has submitted a supplemental New Drug Application to FDA for ZYTIGA(abiraterone acetate). Janssen-Cilag International NV has also sent a type II variation to the European Medicines ...
Related Products
-
CAS 114611-53-9 Abiraterone Acetate Intermediate
-
High Purity Pharmaceutical Chemicals Abiraterone Acetate Powder CAS 154229-18-2 Abiraterone Acetate
-
Best Price API Purity Abiraterone Acetate Powder CAS 154229-18-2 Abiraterone Acetate
-
Raw Materials Abiraterone Acetate CAS 154229-18-2
-
Market 99% Purity Abiraterone Acetate Base Powder Safe Clearance USP Bp Ep Safe Clearance CAS: 154229-18-2 USA Europe Australia
-
Abiraterone Acetate Comply with USP43 Assay99.5%
